# Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma

> **NCT06047197** · PHASE1 · RECRUITING · sponsor: **Beijing Yongtai Ruike Biotechnology Company Ltd** · enrollment: 25 (estimated)

## Conditions studied

- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** RC19D2 cell injection

## Key facts

- **NCT ID:** NCT06047197
- **Lead sponsor:** Beijing Yongtai Ruike Biotechnology Company Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-05
- **Primary completion:** 2026-09-05
- **Final completion:** 2026-12-05
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2024-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06047197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06047197, "Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06047197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*